\nCRISPR-Cas9, son on y\u0131l\u0131n en \u00e7ok konu\u015fulan gen d\u00fczenleme teknolojisi. \u00c7o\u011fu ki\u015fi i\u00e7in h\u00e2l\u00e2 bir \u201claboratuvar arac\u0131\u201d gibi g\u00f6r\u00fcnse de, asl\u0131nda Cas9 proteini ve ona e\u015flik eden rehber RNA (sgRNA) kombinasyonu, do\u011frudan klinikte kullan\u0131lan protein-peptit yap\u0131l\u0131 bir ila\u00e7 platformuna d\u00f6n\u00fc\u015fm\u00fc\u015f durumda. Cas9, bakteriyel k\u00f6kenli bir endon\u00fckleaz proteindir; rehber RNA ile birlikte hedef DNA dizisini tan\u0131r, \u00e7ift zincirli k\u0131r\u0131k olu\u015fturur ve h\u00fccrenin onar\u0131m mekanizmalar\u0131n\u0131 tetikler [doi:10.1126\/science.1231143]<\/strong>.\n<\/p>\n \nGeleneksel k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar, genellikle enzimleri inhibe eder veya resept\u00f6rlere ba\u011flanarak sinyal yolaklar\u0131n\u0131 ge\u00e7ici olarak mod\u00fcle eder. Buna kar\u015f\u0131l\u0131k CRISPR-Cas9, do\u011frudan genomu hedef al\u0131r ve DNA dizisini kal\u0131c\u0131 olarak de\u011fi\u015ftirir. Bu y\u00fczden Cas9 proteini, fonksiyonel olarak \u201cbir kez uyguland\u0131\u011f\u0131nda uzun s\u00fcreli etki\u201d sa\u011flayan protein-peptit yap\u0131l\u0131 bir biyolojik ila\u00e7 gibi de\u011ferlendirilmeye ba\u015flanm\u0131\u015ft\u0131r [doi:10.1038\/nature14544]<\/strong>.\n<\/p>\n \nK\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar genellikle:\n<\/p>\n \nCRISPR-Cas9 tabanl\u0131 protein-peptit yap\u0131l\u0131 ila\u00e7lar ise farkl\u0131 bir paradigma sunuyor:\n<\/p>\n \n\u00d6rne\u011fin k\u00fc\u00e7\u00fck molek\u00fcl bir tirozin kinaz inhibit\u00f6r\u00fc, onkogenik bir kinaz\u0131 ge\u00e7ici olarak bask\u0131larken; CRISPR-Cas9 ile ayn\u0131 kinaz\u0131 kodlayan gende \u201cknock-out\u201d veya mutasyon d\u00fczeltmesi yapmak m\u00fcmk\u00fcn. Bu yakla\u015f\u0131m, kal\u0131tsal hastal\u0131klar ve baz\u0131 kanser t\u00fcrleri i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 bir tedavi stratejisi sunuyor [doi:10.1056\/NEJMoa2034475]<\/strong>.\n<\/p>\n \nBug\u00fcn CRISPR-Cas9 tabanl\u0131 protein-peptit yap\u0131l\u0131 ila\u00e7 adaylar\u0131, \u00f6zellikle hematolojik ve genetik hastal\u0131klarda klinik denemelerde test ediliyor. Orak h\u00fccreli anemi ve beta-talasemi i\u00e7in geli\u015ftirilen ex vivo tedavilerde:\n<\/p>\n \nBu yakla\u015f\u0131m, tek seferlik bir CRISPR-Cas9 m\u00fcdahalesiyle, \u00f6m\u00fcr boyu s\u00fcrebilecek terap\u00f6tik fayda yaratma potansiyeline sahip [doi:10.1056\/NEJMoa2117175]<\/strong>. Benzer \u015fekilde, karaci\u011fer kaynakl\u0131 metabolik hastal\u0131klar ve baz\u0131 kal\u0131tsal g\u00f6z hastal\u0131klar\u0131 i\u00e7in in vivo CRISPR-Cas9 uygulamalar\u0131 da h\u0131zla ilerliyor [doi:10.1038\/s41587-021-01148-4]<\/strong>.\n<\/p>\n \nCRISPR-Cas9 tabanl\u0131 protein-peptit yap\u0131l\u0131 ila\u00e7lar\u0131n en kritik zorlu\u011fu, off-target<\/strong> yani hedef d\u0131\u015f\u0131 gen kesimleri. Cas9 proteini yanl\u0131\u015f DNA b\u00f6lgesine ba\u011flan\u0131p k\u0131r\u0131k olu\u015fturdu\u011funda:\n<\/p>\n \nortaya \u00e7\u0131kabiliyor [doi:10.1038\/nbt.3998]<\/strong>. Bu nedenle ara\u015ft\u0131rmalar \u015fu alanlara yo\u011funla\u015fm\u0131\u015f durumda:\n<\/p>\n \nEtik a\u00e7\u0131dan da \u00f6zellikle embriyo, sperm ve yumurta h\u00fccrelerinde (germ hat) kal\u0131c\u0131 gen d\u00fczenleme giri\u015fimleri, ciddi tart\u0131\u015fmalar yarat\u0131yor ve \u00e7o\u011fu \u00fclkede s\u0131k\u0131 bi\u00e7imde k\u0131s\u0131tlan\u0131yor.\n<\/p>\n \nProtein-peptit yap\u0131l\u0131 CRISPR ila\u00e7lar\u0131, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar\u0131n rakibi olmaktan \u00e7ok, onlar\u0131n tamamlay\u0131c\u0131s\u0131 olmaya aday. \u00d6rne\u011fin kanser tedavisinde:\n<\/p>\n \nBu strateji, hem yan etkileri azaltma hem de tedavi yan\u0131t\u0131n\u0131 uzatma potansiyeli ta\u015f\u0131yor [doi:10.1038\/s41573-020-00092-7]<\/strong>. Gelecekte bir\u00e7ok onkolojik protokolde, CRISPR tabanl\u0131 protein-peptit ila\u00e7lar ile k\u00fc\u00e7\u00fck molek\u00fcllerin kombinasyonlar\u0131n\u0131 daha s\u0131k g\u00f6rmemiz muhtemel.\n<\/p>\n \nCRISPR-Cas9 tabanl\u0131 protein-peptit yap\u0131l\u0131 ila\u00e7lar, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar\u0131n tek ba\u015f\u0131na ula\u015fmakta zorland\u0131\u011f\u0131 bir hedef \u00f6zg\u00fcll\u00fc\u011f\u00fc ve kal\u0131c\u0131l\u0131k sunuyor. Monogenik hastal\u0131klarda, \u201chastal\u0131\u011f\u0131n genetik k\u00f6k nedenini d\u00fczeltme\u201d fikri art\u0131k bilim kurgu de\u011fil, klinik deneme ger\u00e7ekli\u011fi.\n<\/p>\n \nYine de:\n<\/p>\n \ntam olarak \u00e7\u00f6z\u00fcmlenmeden, bu ila\u00e7lar\u0131n yayg\u0131n ve rutin kullan\u0131m\u0131 beklenmemeli. Ancak bug\u00fcn g\u00f6r\u00fclen klinik ba\u015far\u0131lar, CRISPR-Cas9 tabanl\u0131 protein-peptit yap\u0131l\u0131 ila\u00e7lar\u0131n, \u00f6zellikle genetik hastal\u0131klar ve baz\u0131 kanser t\u00fcrleri i\u00e7in gelece\u011fin standart tedavi se\u00e7enekleri aras\u0131na girece\u011fini g\u00fc\u00e7l\u00fc bi\u00e7imde i\u015faret ediyor [doi:10.1056\/NEJMoa2034475]<\/strong>.\n<\/p>\n \nCRISPR-Cas9 ba\u015flang\u0131\u00e7ta bir gen d\u00fczenleme arac\u0131 olarak geli\u015ftirildi; ancak bug\u00fcn Cas9 proteini ve rehber RNA, klinik denemelerde hastaya uygulanan terap\u00f6tik bir kompleks olarak kullan\u0131l\u0131yor. Bu nedenle fonksiyonel a\u00e7\u0131dan protein-peptit yap\u0131l\u0131 bir biyolojik ila\u00e7 platformu olarak kabul ediliyor [doi:10.1126\/science.1231143]<\/strong>.\n<\/p>\n \nEvet. CRISPR-Cas9, do\u011frudan DNA dizisini de\u011fi\u015ftirir. H\u00fccre ya\u015fam\u0131n\u0131 s\u00fcrd\u00fcrd\u00fc\u011f\u00fc ve b\u00f6l\u00fcnd\u00fc\u011f\u00fc s\u00fcrece bu d\u00fczenleme korunur. Bu nedenle etki, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lara k\u0131yasla \u00e7ok daha uzun, \u00e7o\u011fu durumda kal\u0131c\u0131d\u0131r [doi:10.1038\/nature14544]<\/strong>.\n<\/p>\n \nEn b\u00fcy\u00fck risk, hedef d\u0131\u015f\u0131 (off-target) DNA kesimleridir. Cas9 yanl\u0131\u015f b\u00f6lgeyi keserse, istenmeyen mutasyonlar ve potansiyel kanserle\u015fme riski ortaya \u00e7\u0131kabilir. Bu y\u00fczden y\u00fcksek \u00f6zg\u00fcll\u00fckl\u00fc Cas9 varyantlar\u0131 ve optimize rehber RNA tasar\u0131m\u0131 \u00fczerine yo\u011fun \u00e7al\u0131\u015fmalar y\u00fcr\u00fct\u00fcl\u00fcyor [doi:10.1038\/nbt.3998]<\/strong>.\n<\/p>\n \nKlinik denemelerde \u00f6zellikle:\n<\/p>\n \n\u00fczerine yo\u011funla\u015f\u0131lm\u0131\u015f durumda [doi:10.1056\/NEJMoa2117175; doi:10.1038\/s41587-021-01148-4]<\/strong>.\n<\/p>\n \nTamamen yerini almas\u0131 beklenmiyor. Daha \u00e7ok genetik k\u00f6kenli hastal\u0131klarda birinci basamak veya tamamlay\u0131c\u0131 tedavi se\u00e7ene\u011fi olacak. \u00d6zellikle kanserde, CRISPR tabanl\u0131 protein-peptit ila\u00e7lar ile k\u00fc\u00e7\u00fck molek\u00fcl hedefe y\u00f6nelik ajanlar\u0131n kombinasyon halinde kullan\u0131lmas\u0131, daha g\u00fc\u00e7l\u00fc ve uzun s\u00fcreli tedavi yan\u0131tlar\u0131 sa\u011flayabilir [doi:10.1056\/NEJMoa2034475; doi:10.1038\/s41573-020-00092-7]<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":" CRISPR-Cas9 gen d\u00fczenleme teknolojisinin neden protein-peptit yap\u0131l\u0131 bir ila\u00e7 gibi davrand\u0131\u011f\u0131n\u0131, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lardan farklar\u0131n\u0131 ve kal\u0131tsal hastal\u0131klar ile kanserdeki klinik uygulamalar\u0131n\u0131 ke\u015ffedin.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[91],"tags":[820,815,816,819,204,821,818,817],"class_list":["post-10259","post","type-post","status-publish","format-standard","hentry","category-enzimler-biyokimya","tag-biyoteknoloji","tag-crispr-cas9","tag-gen-duzenleme","tag-kalitsal-hastaliklar","tag-kanser-tedavisi","tag-klinik-arastirmalar","tag-kucuk-molekul-ilaclar","tag-protein-peptit-ilaclar"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10259"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10259\/revisions"}],"predecessor-version":[{"id":10260,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10259\/revisions\/10260"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}K\u00fc\u00e7\u00fck Molek\u00fcl \u0130la\u00e7lardan Fark\u0131: Hedefe \u00d6zg\u00fc ve Kal\u0131c\u0131 Gen D\u00fczenleme<\/h2>\n
\n
\n
Klinik Uygulamalar: CRISPR Protein-Peptit \u0130la\u00e7lar\u0131 Hangi Noktada?<\/h2>\n
\n
G\u00fcvenlik, Off-Target Etkiler ve Etik S\u0131n\u0131rlar<\/h2>\n
\n
\n
CRISPR-Cas9 ve K\u00fc\u00e7\u00fck Molek\u00fcl \u0130la\u00e7lar\u0131n Sinerjisi<\/h2>\n
\n
Sonu\u00e7: CRISPR Tabanl\u0131 Protein-Peptit Yap\u0131l\u0131 \u0130la\u00e7lar Gelece\u011fin Yeni Standart\u0131 m\u0131?<\/h2>\n
\n
Kaynaklar<\/h3>\n
\n
S\u0131k Sorulan Sorular (SSS)<\/h2>\n
1. CRISPR-Cas9 ger\u00e7ekten bir \u201cila\u00e7\u201d m\u0131, yoksa sadece laboratuvar arac\u0131 m\u0131?<\/h3>\n
2. CRISPR-Cas9 tedavisinin etkisi kal\u0131c\u0131 m\u0131d\u0131r?<\/h3>\n
3. CRISPR-Cas9 tabanl\u0131 ila\u00e7lar\u0131n en b\u00fcy\u00fck riski nedir?<\/h3>\n
4. CRISPR-Cas9 \u015fu anda hangi hastal\u0131klar\u0131n tedavisinde deneniyor?<\/h3>\n
\n
5. CRISPR-Cas9 k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar\u0131n yerini tamamen alacak m\u0131?<\/h3>\n